No­vo Nordisk’s once-a-day sick­le cell dis­ease drug etavopi­vat cut the rate of pain crises in a year­long mid-stage study.

Gilead and Ar­cel­lx’s ear­ly tri­al da­ta on their mul­ti­ple myelo­ma cell ther­a­py show that pa­tients saw no cas­es of cer­tain de­layed neu­ro­tox­i­c­i­ties, ...

They included a Phase 2 study that the companies hope supports regulatory ... “Our sense from the totality of the efficacy data is that Carvykti remains the most effective BCMA cell-therapy, and with ...

The company’s self-developed original new drug, Chiauranib, combined with PD - (L) 1 monoclonal antibody and standard chemotherapy for the first-line treatment of extensive stage small cell lung ...

Individualized neoantigen therapies aim to elicit antitumor immune responses by creating T-cell responses based on mutations. The trial's estimated primary completion date is May 2033. The phase 3 ...

"Prior to this paper, we had written a paper that observed a similar phase transition in entanglement, in which we had observed phases where measurements of a quantum system preserved or destroyed ...